Biologics and heart failure in rheumatoid arthritis: are we any wiser?
Authors:
- 1 May 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 20 (3) , 327-333
Abstract
Purpose of review To summarize the recent literature concerning the role of TNF-α in heart failure, epidemiology of heart failure in rheumatoid arthritis and risk of heart failure associated with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Recent findings TNF-α has been implicated in the pathogenesis of heart failure. It has direct deleterious effects on the myocardium in the setting of acute injury or chronic heart failure. In animal models, TNF-α is important in cardiac remodeling, leading to cardiac dysfunction following acute injury. Both incident and worsening heart failure have been reported in patients with rheumatoid arthritis who are treated with anti-TNF-α therapy. Recent cohort studies, however, have shown no increased risk and, in some, a protective effect on the risk of heart failure. Certain traditional cardiovascular risk factors have a relatively lesser contribution to cardiovascular morbidity and mortality in patients with rheumatoid arthritis, suggesting that disease-related perturbations of the cytokine network may contribute to the excess risk of heart failure in these patients. Summary Overall mortality in rheumatoid arthritis has remained stagnant despite advances in rheumatoid arthritis and heart failure management and improved cardiovascular mortality in the general population. Heart failure prevalence is increased in patients with rheumatoid arthritis and leads to greater mortality. Despite current expert consensus contraindicating the use of anti-TNF-α agents in patients with moderate to severe heart failure, epidemiological studies in rheumatoid arthritis have not consistently substantiated this association.Keywords
This publication has 60 references indexed in Scilit:
- Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF- antagonistsRheumatology, 2007
- All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonistsAnnals of the Rheumatic Diseases, 2007
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals of the Rheumatic Diseases, 2007
- NO-cGMP and TNF-α counter regulatory system in blood: Understanding the mechanisms leading to myocardial dysfunction and failureBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- Interplay of TNF-α and IL-10 in regulating oxidative stress in isolated adult cardiac myocytesJournal of Molecular and Cellular Cardiology, 2006
- Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled studyArthritis & Rheumatism, 2006
- Safety of extended treatment with anakinra in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of diseaseAnnals of the Rheumatic Diseases, 2000
- The mortality of rheumatoid arthritisArthritis & Rheumatism, 1994